#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	5122	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2415	614.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1545	1545	C	692	C	628	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7998	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3979	601.5	0	.	n	.	0	T695C	SNP	695	695	T	1206	1206	C	592	C,G,A	532,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7998	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3979	601.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1848	1848	A	719	A,G,C	652,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7998	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3979	601.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2482	2482	C	738	C,A	668,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7998	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3979	601.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3108	3108	T	645	T	578	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7998	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3979	601.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2556	2556	A	731	A	665	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	784	folP	852	852	100.0	folP.l15.c4.ctg.1	2064	113.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1351	1353	AGC	176;177;179	A;G;C	158;165;160	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1724	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3888	132.8	1	SNP	p	S91F	0	.	.	271	273	TCC	781	783	TCC	157;158;160	T;C;C	138;144;146	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1724	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3888	132.8	1	SNP	p	D95G	0	.	.	283	285	GAC	793	795	GAC	157;155;155	G;A;C	144;145;141	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1724	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3888	132.8	1	SNP	p	D95N	0	.	.	283	285	GAC	793	795	GAC	157;155;155	G;A;C	144;145;141	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	722	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1866	116.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	731	733	ACC	187;186;187	A;C;C	167;172;169	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	722	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1866	116.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	746	748	CAC	185;185;185	C;A;C	160;170;173	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	722	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1866	116.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	929	931	CAC	201;201;201	C;A;C	192;194;194	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	722	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1866	116.0	1	SNP	p	G45D	0	.	.	133	135	GGC	749	751	GGC	186;187;187	G,T;G;C	168,1;172;170	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	520	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1518	102.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1724	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3612	143.0	1	SNP	p	D86N	0	.	.	256	258	GAC	911	913	GAC	179;179;179	G,A;A;C	161,1;156;163	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1724	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3612	143.0	1	SNP	p	S87I	0	.	.	259	261	AGT	914	916	AGT	178;178;177	A,C;G;T	153,1;162;160	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1724	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3612	143.0	1	SNP	p	S87R	0	.	.	259	261	AGT	914	916	AGT	178;178;177	A,C;G;T	153,1;162;160	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1724	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3612	143.0	1	SNP	p	S87W	0	.	.	259	261	AGT	914	916	AGT	178;178;177	A,C;G;T	153,1;162;160	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1724	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3612	143.0	1	SNP	p	S88P	0	.	.	262	264	TCC	917	919	TCC	177;176;176	T;C;C	155;159;153	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1498	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3144	142.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1767	1769	GGC	181;182;181	G;G,A,T;C,A	166;160,1,1;162,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1568	1570	GCA	185;185;189	G,T;C,A;A,C	161,1;158,1;163,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1571	1573	ATC	189;189;189	A;T,G;C	165;160,1;169	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1583	1585	GTG	192;191;193	G;T;G	173;165;167	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1583	1585	GTG	192;191;193	G;T;G	173;165;167	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2087	2089	ACC	126;126;125	A;C;C,G	112;114;111,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2141	2143	GCG	121;120;120	G;C,G;G,C	109;94,1;100,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2141	2143	GCG	121;120;120	G;C,G;G,C	109;94,1;100,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2264	2266	GGC	116;116;115	G,C;G,T;C	96,2;104,1;102	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2273	2275	GGC	114;113;112	G;G;C	101;100;102	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1168	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2992	117.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2291	2293	CCG	125;125;125	C;C,A;G	110;108,1;108	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1822	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3745	146.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1877	1879	CTG	165;165;166	C;T,C;G	137;143,1;144	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	952	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2367	120.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	603	605	GGC	158;159;160	G;G;C	148;140;142	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	952	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2367	120.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	785	785	C	127	C	114	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	297	91.69	porB1a.l6.c4.ctg.1	1548	19.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1274	1276	AAT	19;19;19	A;A;T	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	297	91.69	porB1a.l6.c4.ctg.1	1548	19.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1277	1279	AAT	19;19;19	A;A;T	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	297	91.69	porB1a.l6.c4.ctg.1	1548	19.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1301	1303	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	297	91.69	porB1a.l6.c4.ctg.1	1548	19.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1324	1326	GTA	15;15;15	G;T;A	15;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	297	91.69	porB1a.l6.c4.ctg.1	1548	19.3	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1336	1336	G	14	G	14	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	T18M	NONSYN	52	54	ACG	337	339	ATG	204;203;202	A;T;G	183;180;175	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	G140R	NONSYN	418	420	GGA	703	705	AGA	191;191;192	A;G;A	174;177;174	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	712	714	CAA	189;189;188	C;A;A	172;173;172	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	844	846	CGA	180;180;179	C;G;A,C	169;167;163,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	S189N	NONSYN	565	567	AGC	850	852	AAC	182;180;179	A;A;C	167;165;165	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	I209M	NONSYN	625	627	ATC	910	912	ATG	186;186;185	A;T;G	172;171;175	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	E210_Y211insR	INS	628	628	G	913	913	G	185	G	171	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	E212L	NONSYN	634	636	GAA	922	924	TTA	184;183;182	T;T;A	171;169;169	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	H213Y	NONSYN	637	639	CAT	925	927	TAT	182;181;182	T;A;T	172;167;169	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	Q214N	NONSYN	640	642	CAA	928	930	AAT	181;180;180	A;A;T,C	170;165;165,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	V215I	NONSYN	643	645	GTT	931	933	ATC	181;180;181	A;T;C	169;161;165	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	S217N	NONSYN	649	651	AGT	937	939	AAT	182;182;182	A;A,C;T	169;170,1;168	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	V242A	NONSYN	724	726	GTT	1012	1014	GCC	181;182;182	G;C;C	162;166;164	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1057	1059	ACG	179;177;177	A;C;G	166;160;159	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1063	1065	GTT	175;174;174	G;T;T	161;159;158	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1171	1173	GAT	170;172;173	G;A;T	147;146;150	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1177	1179	AAC	173;173;174	A;A;C,A	153;149;144,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	914	porB1b	1047	1047	96.95	porB1b.l15.c30.ctg.1	1552	163.8	1	SNP	p	G120K	0	.	.	358	360	GGC	643	645	GGC	197;198;198	G;G;C	175;179;177	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3264	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5562	175.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2376	2378	AAT	188;188;188	A;A;T	178;173;177	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	500	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1528	98.0	1	SNP	p	V57M	1	.	.	169	171	ATG	714	716	ATG	194;194;196	A;T;G	180;180;178	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
